Delivery Order SPE2DB20D2014-SPE2DB25FC56T
- Not listed
- The Defense Logistics Agency awarded a $2,108.70 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,170.50 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This firm fixed price, competitively awarded contract was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in Conshohocken, PA. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 29, 2025. This non-competitive delivery order represents a firm fixed price transaction and is classified as a child contract under AmerisourceBergen's larger contract vehicle with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a $8,495.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 21, 2025. This non-set-aside contract was competitively awarded on July 18, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal healthcare needs, specifically for diabetes...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,257.27 with a firm fixed price structure. The award, issued on July 30, 2025, represents a non-competitive delivery order with a completion date of July 31, 2025. This contract is a child award executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 comprehensive...
- The Defense Logistics Agency awarded a $3,682.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 22, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order executes under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens, valued at $1,862.88. This firm fixed-price delivery order, which concludes on July 24, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,150.32. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $2,108.70 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, using firm fixed-price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed this delivery from its corporate office location. This delivery order represents a child contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,007.80 for NovoLog 100 Unit/ML FlexPen 3ML insulin pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC56TDelivery Order
The Defense Logistics Agency awarded a $2,289.71 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This insulin delivery order exemplifies the company's role in fulfilling essential pharmaceutical needs for the Department of Defense healthcare programs through a flexible and comprehensive contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/25/25 |